Pharmacy World and Science

, Volume 27, Issue 4, pp 285–289 | Cite as

Antipsychotic-induced Extrapyramidal Syndromes in Psychiatric Practice: A Case-control Study

  • I. Schillevoort
  • R. M. C. Herings
  • A. de. Boer
  • H. G. M. Leufkens
  • G. W. K. Hugenholtz
  • W. A. Nolen
  • R. A. C. Roos
Research Article

Abstract

Background: While several clinical trials showed that atypical antipsychotics have a low risk of extrapyramidal side effects (EPS), this observation is not undisputed. This study compared the risk of EPS between specific subgroups of antipsychotics.

Methods: Using the automated dispensing records of a large psychiatric hospital in The Netherlands, we defined cases as first-time users of anticholinergic antiparkinson drugs. Controls were all patients with no recorded use of such medication. Cases and controls were compared with regard to previous use of antipsychotics and relevant co-factors.

Results: Out of 1403 patients, we identified 105 cases and 330 controls. Compared to non-users, antipsychotic-users were 10 times more likely to start with anticholinergic antiparkinson medication (adjusted odds ratio: 10.1; 95 CI 4.6–22.3). Depot and non-depot antipsychotics had similar adjusted odds ratios of 10.9 (95 CI 3.7–32.6) and 8.8 (95% CI 3.8–20.4) respectively. Low and high potency antipsychotics gave odds ratios of 3.0 (95% CI 0.9–10.3) versus 10.8 (95% CI 4.7–25.1). Classical and atypical antipsychotics showed comparable odds ratios: 10.0 (95% CI: 4.4–22.5) versus 8.0 (95% CI: 2.6–24.5). Applied doses of classical and atypical antipsychotic drugs were much lower and more equivalent than those used in previous clincial trials.

Conclusions: Low potency antipsychotics had a much lower risk of EPS than other antipsychotics. However, we did not corroborate the reduced risk with atypical antipsychotics observed in several clinical trials. This discrepancy may result from the high and non-equivalent doses of classical antipsychotics used in many of these trials.

Key words

ADRs Antipsychotics Atypical antipsychotics Extrapyramidal syndromes Parkinsonism Schizophrenia Side effect 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Murray, CJL, Lopez, AD. 1996The Global Burden of Disease and Injury Series, Vol 1: a Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020Harvard University PressCambridge, MAGoogle Scholar
  2. 2.
    Gijsen R, Roos MJC. Hoe vaak komt schizofrenie voor? In: Volksgezondheid toekomst verkenning, Nationaal kompas volksgezondheid. Bilthoven: RIVM, 2004.Google Scholar
  3. 3.
    Casey, DE. 1991Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesiaSchizophr Res410920CrossRefPubMedGoogle Scholar
  4. 4.
    Schwartz, JT, Brotman, AW. 1992A clinical guide to antipsychotic drugsDrugs4498192PubMedGoogle Scholar
  5. 5.
    Chouinard, G,  et al. 1993A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patientsJ Clin Psychopharmacol132540PubMedGoogle Scholar
  6. 6.
    Beasley, CM,Jr,  et al. 1997Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trialEur Neuropsychopharmacol712537CrossRefPubMedGoogle Scholar
  7. 7.
    Zimbroff, DL,  et al. 1997Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study GroupAm J Psychiatry15478291PubMedGoogle Scholar
  8. 8.
    Hoyberg, OJ,  et al. 1993Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbationsActa Psychiatr Scand88395402PubMedGoogle Scholar
  9. 9.
    Min, SK,  et al. 1993Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trialYonsei Med J3417990PubMedGoogle Scholar
  10. 10.
    Miller, CH,  et al. 1998The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychoticsJ Clin Psychiatry596975Google Scholar
  11. 11.
    Rosebush, PI, Mazurek, MF. 1999Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidoneNeurology527825PubMedGoogle Scholar
  12. 12.
    Standaert, DG, Young, AB. 1995

    Treatment of central nervous system degenerative disorders

    Goodman, LSGilman, AHardman, JGGilman, AGLimbird, LE eds. The Pharmacological Basis of Therapeutics9McGraw-HillNew York50420
    Google Scholar
  13. 13.
    Kuy, A. 1998Farmacotherapeutisch KompasCentrale Medisch Farmaceutische Commissie van de ZiekenfondsraadAmstelveenGoogle Scholar
  14. 14.
    George, CF. 1997British National Formulary, September 1997British Medical Association and the Royal Pharmaceutical Society of Great BritainLondonGoogle Scholar
  15. 15.
    Egberts, AC,  et al. 1997Channeling of three newly introduced antidepressants to patients not responding satisfactorily to previous treatmentJ Clin Psychopharmacol1714955CrossRefPubMedGoogle Scholar
  16. 16.
    Anonymous, Anatomical Therapeutic Chemical (ATC)1998Classification Index: Including Defined Daily Doses (DDD) for Plain SubstancesWorld Health OrganizationOslo, NorwayGoogle Scholar
  17. 17.
    Bollini, P,  et al. 1994Antipsychotic drugs: is more worse? A meta-analysis of the published randomized control trialsPsychol Med2430716PubMedGoogle Scholar
  18. 18.
    Jimenez Jimenez, FJ, Garcia Ruiz, PJ, Molina, JA. 1997Drug-induced movement disordersDrug Saf16180204PubMedGoogle Scholar
  19. 19.
    Greenland, S. 1989Modeling and variable selection in epidemiologic analysisAm J Public Health793409PubMedGoogle Scholar
  20. 20.
    Schlesselman, JJ. 1982Case–control studiesOxford University PressNew York2006Google Scholar
  21. 21.
    Avorn, J,  et al. 1995Neuroleptic drug exposure and treatment of parkinsonism in the elderly: a case–control studyAm J Med994854CrossRefPubMedGoogle Scholar
  22. 22.
    Ganzini, L,  et al. 1991Acute extrapyramidal syndromes in neuroleptic-treated elders: a pilot studyJ Geriatr Psychiatry Neurol42225PubMedGoogle Scholar
  23. 23.
    Ayd, F. 1961A survey of drug-induced extrapyramidal reactionsJAMA175105560Google Scholar
  24. 24.
    Menkes, DB,  et al. 1987Anticholinergic equivalents and parkinsonism: a model for predicting side-effects of antipsychotic drugsInt Clin Psychopharmacol25567PubMedGoogle Scholar
  25. 25.
    Marder, SR, Meibach, RC. 1994Risperidone in the treatment of schizophreniaAm J Psychiatry15182535PubMedGoogle Scholar
  26. 26.
    Rothman, KJ, Greenland, S. 1998Modern Epidemiology2Lippincott-RavenPhiladelphiaGoogle Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  • I. Schillevoort
    • 1
  • R. M. C. Herings
    • 1
  • A. de. Boer
    • 1
  • H. G. M. Leufkens
    • 1
  • G. W. K. Hugenholtz
    • 2
  • W. A. Nolen
    • 2
    • 3
  • R. A. C. Roos
    • 4
  1. 1.Department of Pharmacoepidemiology & PharmacotherapyUtrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht UniversityUtrechtThe Netherlands
  2. 2.HC Rümke GroepUtrechtThe Netherlands
  3. 3.University Medical CentreUtrechtThe Netherlands
  4. 4.Department of NeurologyLeiden University Medical CentreLeidenThe Netherlands

Personalised recommendations